Evidence map›Paper›PMID 25688119›Full record

ArticleNeuro-oncology2015

Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.

Cynthia Wetmore, James Boyett, Shaoyu Li, Tong Lin, Anne Bendel, Amar Gajjar, Brent A Orr

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Small-Molecule Drugs in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cynthia WetmoreDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
James BoyettDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
Shaoyu LiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
Tong LinDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
Anne BendelDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
Amar GajjarDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
Brent A OrrDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., A.G.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (J.B., S.L., T.L.); Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota (A.B.); Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.).
St. Jude Children's Research Hospital · USChildren's Minnesota · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
NCI NIH HHS P30 CA021765NCI NIH HHS P30 CA21765
6 · The paper itself

Abstract

backgroundAurora Kinase A (AURKA) encodes a protein that regulates the formation and stability of the mitotic spindle and is highly active in atypical teratoid rhabdoid tumors (ATRT) through loss of the INI1 tumor suppressor gene. Alisertib (MLN8237) inhibits AURKA in vitro and in vivo. Given the strong preclinical data supporting the use of alisertib for ATRT patients, we sought and obtained permission to use alisertib in single patient treatment plans for 4 recurrent pediatric ATRT patients.

methodsPatients with recurrent or progressive ATRT received alisertib 80 mg/m(2) by mouth once daily for 7 days of a 21-day treatment cycle. Disease evaluation (MRI of brain and spine and lumbar puncture) was done after 2 cycles of alisertib and every 2-3 cycles thereafter for as long as the patients remained free from tumor progression.

resultsFour patients with median age of 2.5 years (range, 1.39-4.87 y) at diagnosis received alisertib 80 mg/m(2) by mouth once daily for 7 days of a 21-day treatment cycle, and all 4 patients had disease stabilization and/or regression after 3 cycles of alisertib therapy. Two patients continued to have stable disease regression for 1 and 2 years, respectively, on therapy.

conclusionsSingle-agent alisertib produced marked and durable regression in disease burden, as detected by brain and spine MRI and by evaluation of spinal fluid cytology. Alisertib has moderate but manageable toxicities, and its chronic administration appears feasible in this pediatric population. These novel data support the incorporation of alisertib in future therapeutic trials for children with ATRT.

Indexed as

Antineoplastic AgentsAurora Kinase AAzepinesBrainBrain NeoplasmsChild, PreschoolFemaleHumansInfantMalePyrimidinesRhabdoid TumorTeratomaTreatment OutcomeAntineoplastic AgentsAURKA protein, humanAurora Kinase AAzepinesMLN 8237PyrimidinesATRTAurora kinase Abrain tumorpediatrictargeted therapy

Identifiers

PMID25688119
PMCPMC4483126
OpenAlexW2008769862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.